Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

被引：0
|
作者：
Zeqing Zhang
Xi Chen
Puhan Lu
Jianhua Zhang
Yongping Xu
Wentao He
Mengni Li
Shujun Zhang
Jing Jia
Shiying Shao
Junhui Xie
Yan Yang
Xuefeng Yu
机构：
[1] Huazhong University of Science and Technology,Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Glucagon-like peptide-1 agonists; Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes mellitus; Cardiovascular outcomes; Acute pancreatitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Bessette, Lily G.
    Najafzadeh, Mehdi
    Wexler, Deborah J.
    Franklin, Jessica
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Koeneman, Lisette
    Schneeweiss, Sebastian
    DIABETES, 2020, 69
  • [42] GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes
    Xu, Yang
    Fu, Edouard L.
    Clase, Catherine M.
    Mazhar, Faizan
    Jardine, Meg J.
    Carrero, Juan J.
    KIDNEY INTERNATIONAL, 2022, 101 (02) : 360 - 368
  • [43] The risk of acute pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors: a retrospective observational cohort study
    Koro, C. E.
    Sowell, M. O.
    Stender, M.
    Chhabra, P.
    Allen, J. K.
    Krzywy, H. J.
    DIABETOLOGIA, 2013, 56 : S183 - S184
  • [44] Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
    Longato, Enrico
    Di Camillo, Barbara
    Sparacino, Giovanni
    Gubian, Lorenzo
    Avogaro, Angelo
    Fadini, Gian Paolo
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [45] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [46] Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis
    Roddick, A.
    Zheng, S. L.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2471 - 2471
  • [47] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [48] Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors
    Egan, Aoife M.
    Montori, Victor M.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (02) : JC2 - JC2
  • [49] GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
    Marx, Nikolaus
    Husain, Mansoor
    Lehrke, Michael
    Verma, Subodh
    Sattar, Naveed
    CIRCULATION, 2022, 146 (24) : 1882 - 1894
  • [50] Effect of a DPP-4 inhibitor on liver and Heart fat and cardiovascular risk in Type II diabetic patients
    Kosi, Lana
    Chmelik, Marek
    Trattnig, Siegfried
    Strametz-Juranek, Jeanette
    Kautzky-Willer, Alexandra
    WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 : S6 - S6
12345